PURE Bioscience (OTCMKTS: PURE) and Tronox (OTCMKTS:TROX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Profitability

This table compares PURE Bioscience and Tronox’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PURE Bioscience -342.05% -208.61% -110.10%
Tronox N/A N/A N/A

Insider and Institutional Ownership

0.2% of PURE Bioscience shares are owned by institutional investors. 16.4% of PURE Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for PURE Bioscience and Tronox, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PURE Bioscience 0 0 0 0 N/A
Tronox 0 0 3 0 3.00

Tronox has a consensus price target of $35.00, suggesting a potential upside of Infinity. Given Tronox’s higher probable upside, analysts clearly believe Tronox is more favorable than PURE Bioscience.

Valuation & Earnings

This table compares PURE Bioscience and Tronox’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
PURE Bioscience $1.83 million 37.12 -$6.26 million ($0.10) -10.00
Tronox N/A N/A N/A N/A N/A

Tronox has higher revenue, but lower earnings than PURE Bioscience.

Summary

Tronox beats PURE Bioscience on 5 of the 8 factors compared between the two stocks.

PURE Bioscience Company Profile

PURE Bioscience, Inc. is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC). It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains and food processors. It is testing and continuing development of PURE Control to utilize PURE Control as a direct food contact processing aid for raw meats, including beef and pork. In addition to PURE Hard Surface and PURE Control, it manufactures and sells SDC-based products for end use; products preserved with SDC, and SDC as a raw material ingredient for manufacturing use. These products include PURE Multi-Purpose and Floor Cleaner Concentrate, PURE Multi-Purpose Hi-Foam Cleaner Concentrate, Axen 30, Axenohl and SILVERION.

Tronox Company Profile

Tronox Limited is engaged in production and marketing of titanium bearing mineral sands and titanium dioxide pigment (TiO2). The Company’s TiO2 products are critical components of everyday applications, such as coatings, plastics, paper and other applications. The Company’s mineral sands business consists primarily of two product streams: titanium feedstock and zircon. The Company operates in three segments: mineral sands, pigment and corporate and other. The corporate and other include its electrolytic manufacturing business. It has operations in North America, Europe, South Africa and the Asia-Pacific region. The Company operates three TiO2 facilities at the locations in Hamilton, Mississippi, Botlek, The Netherlands, and Kwinana, Western Australia, representing approximately 465,000 tons of annual TiO2 production capacity.

Receive News & Stock Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related stocks with our FREE daily email newsletter.